NIH scientists and investigators abroad have identified the first enzyme inhibitor long thought to be a potential drug target for fighting disease-causing parasites and bacteria. The teams, led by NIH’s National Center for Advancing Translational Sciences (NCATS) and University of Tokyo researchers, sorted through more than one trillion cyclic peptides to uncover two that could shut down the enzyme.
The finding (“Macrocycle peptides delineate locked-open inhibition mechanism for microorganism phosphoglycerate mutases”), reported in Nature Communications, could set the stage for the potential development of new types of antimicrobial drugs, according to the team.
“The work is an excellent demonstration of how NCATS delivers on its mission to provide improvements in translational processes,” said Anton Simeonov, Ph.D., scientific director, NCATS division of preclinical innovation. “Scientists have shown that a therapeutic target, previously considered undruggable by pharmaceutical companies, is actually druggable through a nontraditional therapeutic agent.”
The target enzyme, cofactor-independent phosphoglycerate mutase (iPGM), is found in both parasites and bacteria. Several types of parasitic roundworms have iPGM, including Brugia malayi and Onchocerca volvulus, which infect roughly 150 million people living mostly in tropical regions. These parasites can cause devastating infectious diseases, such as river blindness. The enzyme also is found in bacteria, including Staphylococcus aureus, which can cause the hospital-borne infection MRSA (methicillin-resistant S. aureus), and Bacillus anthracis, which causes anthrax.
“Several infectious organisms are potentially susceptible to an iPGM inhibitor,” said co-corresponding author James Inglese, Ph.D., director, NCATS Assay Development and Screening Technology Laboratory. “The team dubbed the inhibitor peptides ‘ipglycermides,’ which represent a powerful class of iPGM inhibitors. In theory, such a drug could become a broad spectrum antiparasitic and antibacterial treatment.”
Current antiparasitic drugs, such as ivermectin, mainly work on the early larval stages of the worm. Such a treatment must be given annually or semiannually for as long as a decade. For years, scientists have tried to find a more effective drug that also worked against the adult worm and the later stages of infection. Earlier studies by Dr. Inglese’s collaborators at New England Biolabs in Ipswich, MA, showed that iPGM is one of many essential enzymes the roundworm needs to survive. It is part of the process of glycolysis, which helps make energy for cells.
While the same important process occurs in human cells, it relies on a different form of the enzyme. As a result, a drug that targets iPGM and kills the roundworm would likely leave the human counterpart alone. Such a drug might work on all life stages of the worm, and the infection could possibly be treated acutely, akin to an antibiotic. However, previous attempts at finding a compound to block the enzyme have failed.
Most enzymes have pocket-shaped “active sites” into which a molecule fits, and on which the enzyme acts. Small-molecule drugs can fit in active sites and prevent, or inhibit, the enzyme from doing its biological job. But iPGM and other similar enzymes are different. iPGM has a short-lived, temporary active site, making it practically impossible to find a small-molecule drug that can block the enzyme.
Because of the enzyme’s unusual design, the NCATS-led team sought a different type of drug than the typical small-molecule drugs. Dr. Inglese collaborated with co-corresponding author Hiroaki Suga, Ph.D., at the University of Tokyo, to build a library mixture of more than one trillion small peptides. The team went one step further, adding an amino acid to the peptides to create ring-shaped cyclic peptides, which the scientists hypothesized would have the needed shape and structure to attach to the enzyme surface and disable the enzyme.
The researchers sifted repeatedly through the cyclic peptides to find which would stick most tightly to the enzyme. They found two cyclic peptides that both bound tightly to only the iPGM enzyme and also shut down its activity.
The team subsequently worked with structural biologists at the University of Kansas, Lawrence, to determine the structure of the iPGM-cyclic peptide arrangement, showing how the peptide prevented the enzyme from working properly. “The cyclic peptide has amazingly tight and selective affinity for iPGM, like an antibody” according to Dr. Inglese.
The group’s next steps will be to find ways for cyclic peptides to enter cells. “If we can find ways to put cyclic peptides into cells, then this would open up new targets that small-molecule drugs have a difficult time addressing,” continued Dr. Inglese. “Ipglycermides represent a fertile yet uncultivated landscape between small-molecule drugs and protein biologics.”
Researchers from other institutions, including the National Institute of Standards and Technology, Gaithersburg, MD, the National Heart, Lung and Blood Institute, and Argonne National Laboratory also participated in the work.